UCB presented Bimzelx data. UCB stock loses 1.06 percent.??

Published on 10/13/2026 at 10:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bimzelx sales reached EUR 1.52 billion in the first half of 2026. UCB stock costs EUR 204.70 on October 13, 2026 versus the Xetra close of EUR 206.90.

Key points in brief

UCB presented Bimzelx data showing 47.40 percent lesion resolution after three years in an early-treatment group.
Bimzelx sales reached EUR 1.52 billion in the first half of 2026, while UCB reported EUR 4.27 billion quarterly revenue.
UCB stock was EUR 204.70 at Lang & Schwarz on October 13, 2026, down 1.06 percent versus the Xetra close of EUR 206.90.
Barclays maintained a Hold rating with a EUR 260.00 price target on October 2, 2026.

Moderner Biopharma-Forschungscampus mit Glasgebäuden und Laborpersonal in Brüssel bei Tageslicht — UCB S.A. mit ISIN BE0003739530 zeigt modernen Forschungscampus in Brüssel mit Laborpersonal in Glasgebäuden, Illustration mit AI erstellt.

UCB stock was trading at EUR 204.70 at Lang & Schwarz on October 13, 2026 at 10:49 a.m. CEST, down 1.06 percent versus the Xetra close of EUR 206.90 on October 12, 2026. The company had presented three-year Bimzelx data on September 30, 2026, with complete inflammatory-lesion resolution reaching 47.40 percent in patients treated earlier after diagnosis versus 33.30 percent in patients with a longer diagnostic history, according to BFM Bourse.

Three dated operating signals

On September 30, 2026, the Bimzelx data added a measurable clinical readout to UCB's immunology growth story. In the same three-year analysis, 67.30 percent of biologic-naive patients achieved complete tunnel clearance, compared with 47.70 percent among patients previously exposed to biologic treatment, according to BFM Bourse.

On June 30, 2026, UCB reported quarterly revenue of EUR 4.27 billion and net profit of EUR 1.11 billion, up from EUR 3.49 billion in revenue and EUR 475.00 million in net profit a year earlier, according to Markets Insider. The comparison gives investors a clearer anchor than the clinical headline alone: commercial execution and product uptake remain central to the valuation debate.

What does the pipeline mean?

UCB's investor materials list Bimzelx sales of EUR 1.52 billion in the first half of 2026 and peak-sales guidance above EUR 7.00 billion. The same page lists first-half sales of EUR 239.00 million for Fintepla, EUR 192.00 million for Rystiggo and EUR 139.00 million for Zilbrysq, showing that the growth case extends beyond one medicine, according to UCB.

The counterweight is valuation sensitivity. Barclays maintained a Hold rating and a EUR 260.00 price target on October 2, 2026, while the consensus average cited in the same report was EUR 278.00, according to Markets Insider. The gap between the Hold view and the higher consensus target underlines the importance of execution against the pipeline milestones.

Upcoming clinical milestones

UCB's pipeline identifies fourth-quarter 2026 topline results for STACCATO alprazolam and first-half 2027 topline results for Bimzelx in hidradenitis suppurativa. Those dates are development milestones rather than financial reporting dates, but they provide concrete markers for the product-led growth narrative, according to UCB.

At Lang & Schwarz, UCB was trading at EUR 204.70 on October 13, 2026 at 10:49 a.m. CEST, down 1.06 percent versus the Xetra close of EUR 206.90 on October 12, 2026. The further course of trading is shown by the continuously updated real-time quote of UCB stock.